[HTML][HTML] Pharmacokinetic and pharmacodynamic responses to clopidogrel: evidences and perspectives
Clopidogrel has significantly reduced the incidence of recurrent atherothrombotic events in
patients with acute coronary syndrome (ACS) and in those undergoing percutaneous …
patients with acute coronary syndrome (ACS) and in those undergoing percutaneous …
[PDF][PDF] Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives
YJ Zhang, MP Li, J Tang… - Int. J. Environ. Res …, 2017 - pdfs.semanticscholar.org
Clopidogrel has significantly reduced the incidence of recurrent atherothrombotic events in
patients with acute coronary syndrome (ACS) and in those undergoing percutaneous …
patients with acute coronary syndrome (ACS) and in those undergoing percutaneous …
Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives
YJ Zhang, MP Li, J Tang… - International journal of …, 2017 - pubmed.ncbi.nlm.nih.gov
Clopidogrel has significantly reduced the incidence of recurrent atherothrombotic events in
patients with acute coronary syndrome (ACS) and in those undergoing percutaneous …
patients with acute coronary syndrome (ACS) and in those undergoing percutaneous …
[HTML][HTML] Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives
YJ Zhang, MP Li, J Tang, XP Chen - International Journal of …, 2017 - ncbi.nlm.nih.gov
Clopidogrel has significantly reduced the incidence of recurrent atherothrombotic events in
patients with acute coronary syndrome (ACS) and in those undergoing percutaneous …
patients with acute coronary syndrome (ACS) and in those undergoing percutaneous …
Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives
YJ Zhang, MP Li, J Tang, XP Chen - IJERPH, 2017 - ideas.repec.org
Clopidogrel has significantly reduced the incidence of recurrent atherothrombotic events in
patients with acute coronary syndrome (ACS) and in those undergoing percutaneous …
patients with acute coronary syndrome (ACS) and in those undergoing percutaneous …
Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives
YJ Zhang, MP Li, J Tang, XP Chen - IJERPH, 2017 - econpapers.repec.org
Clopidogrel has significantly reduced the incidence of recurrent atherothrombotic events in
patients with acute coronary syndrome (ACS) and in those undergoing percutaneous …
patients with acute coronary syndrome (ACS) and in those undergoing percutaneous …
Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives.
YJ Zhang, MP Li, J Tang, XP Chen - International Journal of …, 2017 - europepmc.org
Clopidogrel has significantly reduced the incidence of recurrent atherothrombotic events in
patients with acute coronary syndrome (ACS) and in those undergoing percutaneous …
patients with acute coronary syndrome (ACS) and in those undergoing percutaneous …
Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives
Z Yan-Jiao, L Mu-Peng, J Tang… - International Journal of …, 2017 - search.proquest.com
Clopidogrel has significantly reduced the incidence of recurrent atherothrombotic events in
patients with acute coronary syndrome (ACS) and in those undergoing percutaneous …
patients with acute coronary syndrome (ACS) and in those undergoing percutaneous …